

# COVID-19 natural immunity

Scientific brief

10 May 2021



## Key Messages:

- Within 4 weeks following infection, 90-99% of individuals infected with the SARS-CoV-2 virus develop detectable neutralizing antibodies.
- The strength and duration of the immune responses to SARS-CoV-2 are not completely understood and currently available data suggests that it varies by age and the severity of symptoms. Available scientific data suggests that in most people immune responses remain robust and protective against reinfection for at least 6-8 months after infection (the longest follow up with strong scientific evidence is currently approximately 8 months).
- Some variant SARS-CoV-2 viruses with key changes in the spike protein have a reduced susceptibility to neutralization by antibodies in the blood. While neutralizing antibodies mainly target the spike protein, cellular immunity elicited by natural infection also target other viral proteins, which tend to be more conserved across variants than the spike protein. The ability of emerging virus variants (variants of interest and variants of concern) to evade immune responses is under investigation by researchers around the world.
- There are many available serologic assays that measure the antibody response to SARS-CoV-2 infection, but at the present time, the correlates of protection are not well understood.

## Objective of the scientific brief

This scientific brief replaces the WHO Scientific Brief entitled “‘Immunity passports’ in the context of COVID-19”, published 24 April 2020.<sup>1</sup> This update is focused on what is currently understood about SARS-CoV-2 immunity from natural infection. More information about considerations on vaccine certificates or “passports” will be covered in an update of WHO interim guidance, as requested by the COVID-19 emergency committee.<sup>2</sup>

## Methods

A rapid review on the subject was undertaken and scientific journals were regularly screened for articles on COVID-19 immunity to ensure to include all large and robust studies available in the literature at the time of writing.

## COVID-19 immune responses to natural infection

Prior exposure to SARS-CoV-2 can be assessed by detecting the presence of virus-specific antibodies in serum. Functional neutralizing antibodies (NAb) are those able to neutralize the virus by blocking its entry into the cell.

Large cohort studies have reported that 90-99% of SARS-CoV-2 infected individuals develop neutralizing antibodies within 2-4 weeks after infection.<sup>3-7</sup> A small proportion of individuals do not develop NAb after SARS-CoV-2 infection for reasons that are unclear.<sup>7</sup> Individuals with mild or asymptomatic infection tend to have lower antibody levels than those with severe disease, and some studies have suggested that in some individuals waning of antibody levels occurs within several months after infection.<sup>6-10</sup> Studies aimed to detect immunological memory including the assessment of cellular immunity by testing for the presence of memory B cells, and CD4<sup>+</sup> and CD8<sup>+</sup> T cells, observed robust immunity at 6 months post-infection in 95% of subjects under study, which included individuals with asymptomatic, mild, moderate and severe infections.<sup>11</sup>

## Correlates of protection against disease

How much cellular versus humoral immunity contributes to protection after natural infection is not fully understood. Studies point at NAb as a key element of immunoprotection, with cellular immunity likely to provide additional longer-term protection especially against severe disease and death.<sup>12–15</sup> How long overall protection may last remains unclear, and this may differ depending on the disease severity.<sup>7</sup> For other human coronaviruses (hCoV), hCoV-OC43, hCoV-229E, hCoV-NL63 and hCoV-HKU-1, which cause the common cold, antibodies last for at least a year after infection with significant inter-human variability,<sup>16</sup> while antibodies to more closely related MERS-CoV and SARS-CoV-1, which cause, respectively, middle east respiratory syndrome and severe acute respiratory syndrome, can be detected for years.<sup>17–21</sup>

## Reinfection

Though rarely reported to date, reinfection with SARS-CoV-2 can occur. Four large studies from the United Kingdom, the United States of America and Denmark estimated that infection with SARS-CoV-2 provided 80-90% protection from reinfection up to 7 months, and up to 94% protection against symptomatic disease.<sup>22–25</sup> The level of protection against re-infection as assessed by PCR positivity was estimated to be 50% in people aged over 65 years old.<sup>24</sup>

## SARS-CoV-2 variants and implications for immunity

The more the SARS-CoV-2 virus circulates, the more opportunities it has to change through natural evolution. The emergence of virus variants can pose new challenges. Currently, three virus variants, B.1.1.7, B.1.351 and P.1, with increased transmissibility or potential to partially escape immunity, are characterized as global Variants of Concern (VOC) by WHO and are circulating in many countries. Evidence of reduced susceptibility to neutralization by serum antibodies of some SARS-CoV-2 variants (*e.g.* P.1 and B.1.351) to natural (or vaccine-induced) neutralizing antibodies has been reported,<sup>26–29</sup> raising the concern that reinfection after natural infection (or breakthrough infection after vaccination) may increase in settings where these variants broadly circulate.<sup>30</sup> Of note, recent studies found that current global VOCs are unlikely to have an impact on CD4<sup>+</sup> and CD8<sup>+</sup> T cell reactivity in COVID-19 exposed donors and vaccinees, but how this observation applies to protection against reinfection or breakthrough infection after vaccination remains unclear.

## Measuring immune responses

The immune response following infection with a virus can be measured by the detection of virus-specific antibodies such as IgA, IgM, IgG or total antibodies through immunoassays, as well as by the detection of sensitized memory B cells and/or CD4<sup>+</sup> and CD8<sup>+</sup> T cells, which require more complicated assays. The most commonly measured immune response is the presence of antibodies in serum. Serologic assays to detect the antibody response are usually based on enzyme immunoassays, which detect the presence of virus-specific antibodies in the blood or by live or pseudo-virus neutralization assays, which detect functional NAb. While serologic testing has limited use in clinical management because it does not capture active infection, it can be very useful in determining the extent of infection or estimating attack rates in given populations.

Interpreting the results of serologic testing, however, is complex: there are several antibody types and subtypes and multiple antigenic determinants/epitopes that can be used to target these antibodies, and the results may differ substantially depending on the combinations chosen. The results will also depend on the manufacturing specifics of the assay used. The most frequently used assays for detection of antibodies to SARS-CoV-2 are enzyme-linked immunosorbent tests, chemiluminescent tests, and lateral flow rapid diagnostic tests (RDTs). Advice on the use of RDTs for antibody detection is available on the WHO website.<sup>32</sup>

## Conclusions

Current evidence points to most individuals developing strong protective immune responses following natural infection with SARS-CoV-2. However, inaccurate immunodiagnostic tests may falsely indicate infected individuals as naïve to the virus (not previously infected) or may falsely label non-infected people as positive for immune markers of recent infection.

To conclude, available tests and current knowledge do not tell us about the duration of immunity and protection against reinfection, but recent evidence suggests that natural infection may provide similar protection against symptomatic disease as vaccination, at least for the available follow up period.<sup>33</sup> The emergence of variants of concern poses challenges and their potential to evade immunity elicited by either natural infection or by vaccination, needs to be closely monitored.

## Plans for updating

WHO continues to monitor the situation closely for any changes that may affect the information in this Scientific brief. Should any factors change, WHO will issue a further update. Otherwise, the validity of this brief will be reviewed 3 months after the date of publication.

## Contributors

Lorenzo Subissi, Mick Mulders, Martin Friede, Maria Van Kerkhove, Mark Perkins.

## Acknowledgments

We thank Stanley Perlman for critical reading of this scientific brief.

## References

1. World Health Organization. “Immunity passports” in the context of COVID-19. Available from: <https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19>
2. World Health Organization. Statement on the seventh meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic. Available from: [https://www.who.int/news/item/19-04-2021-statement-on-the-seventh-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-coronavirus-disease-\(covid-19\)-pandemic](https://www.who.int/news/item/19-04-2021-statement-on-the-seventh-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic)
3. Wajnberg A, Mansour M, Leven E, et al. Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. *Lancet Microbe* [Internet] 2020 [cited 2021 Mar 26];1(7):e283–9. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2666524720301208>
4. Guthmiller JJ, Stovicek O, Wang J, et al. SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike. *mBio* [Internet] 2021 [cited 2021 Mar 26];12(1):e02940-20, /mbio/12/1/mBio.02940-20.atom. Available from: <https://mbio.asm.org/content/12/1/e02940-20>
5. Wu J, Liang B, Chen C, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. *Nat Commun* 2021;12(1):1813.
6. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *The Lancet* [Internet] 2021 [cited 2021 Apr 22];397(10270):220–32. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0140673620326568>
7. Arkhipova-Jenkins I, Helfand M, Armstrong C, et al. Antibody Response After SARS-CoV-2 Infection and Implications for Immunity : A Rapid Living Review. *Ann Intern Med* 2021;
8. Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat Microbiol* [Internet] 2020 [cited 2021 Mar 26];5(12):1598–607. Available from: <http://www.nature.com/articles/s41564-020-00813-8>
9. Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* [Internet] 2020 [cited 2021 Apr 22];26(8):1200–4. Available from: <http://www.nature.com/articles/s41591-020-0965-6>
10. Wheatley AK, Juno JA, Wang JJ, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. *Nat Commun* [Internet] 2021 [cited 2021 Apr 22];12(1):1162. Available from: <http://www.nature.com/articles/s41467-021-21444-5>
11. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* [Internet] 2021 [cited 2021 Mar 26];371(6529):eabf4063. Available from: <https://www.sciencemag.org/lookup/doi/10.1126/science.abf4063>
12. Schwarzkopf S. Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2–Specific IgG. *Emerg Infect Dis* [Internet] Available from: [https://wwwnc.cdc.gov/eid/article/27/1/20-3772\\_article#suggestedcitation](https://wwwnc.cdc.gov/eid/article/27/1/20-3772_article#suggestedcitation)
13. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell* 2020;183(1):158-168.e14.
14. Wheatley AK, Juno JA, Wang JJ, et al. Evolution of immunity to SARS-CoV-2 [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2020 [cited 2021 Mar 26]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.09.09.20191205>
15. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. *The Lancet* [Internet] 2020 [cited 2021 Apr 16];396(10262):1595–606. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0140673620321371>

16. Edridge AWD, Kaczorowska J, Hoste ACR, et al. Seasonal coronavirus protective immunity is short-lasting. *Nat Med* [Internet] 2020 [cited 2021 Mar 26];26(11):1691–3. Available from: <http://www.nature.com/articles/s41591-020-1083-1>
17. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. *Nat Commun* [Internet] 2020 [cited 2021 Apr 15];11(1):4704. Available from: <http://www.nature.com/articles/s41467-020-18450-4>
18. Guo X, Guo Z, Duan C, et al. Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2020 [cited 2021 Apr 15]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.02.12.20021386>
19. Wu L-P, Wang N-C, Chang Y-H, et al. Duration of Antibody Responses after Severe Acute Respiratory Syndrome. *Emerg Infect Dis* [Internet] 2007 [cited 2021 Apr 15];13(10):1562–4. Available from: [http://wwwnc.cdc.gov/eid/article/13/10/07-0576\\_article.htm](http://wwwnc.cdc.gov/eid/article/13/10/07-0576_article.htm)
20. Anderson DE, Tan CW, Chia WN, et al. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. *Emerg Microbes Infect* 2020;9(1):900–2.
21. Alshukairi AN, Zhao J, Al-Mozaini MA, Wang Y, Dada A, Baharoon SA, et al. Longevity of Middle East respiratory syndrome coronavirus antibody responses in humans, Saudi Arabia. *Emerg Infect Dis*. 2021. *Emerg Infect Dis*
22. Harvey RA, Rassen JA, Kabelac CA, et al. Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. *JAMA Intern Med* [Internet] 2021 [cited 2021 Mar 26]; Available from: <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2776810>
23. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J Med* [Internet] 2021 [cited 2021 Mar 26];384(6):533–40. Available from: <http://www.nejm.org/doi/10.1056/NEJMoa2034545>
24. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *The Lancet* [Internet] 2021 [cited 2021 Mar 27];397(10280):1204–12. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0140673621005754>
25. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *The Lancet* [Internet] 2021 [cited 2021 Apr 15];S0140673621006759. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0140673621006759>
26. Wang P, Nair MS, Liu L, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. *Nature* [Internet] 2021 [cited 2021 Mar 30]; Available from: <http://www.nature.com/articles/s41586-021-03398-2>
27. Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. *Nat Med* [Internet] 2021 [cited 2021 Mar 30]; Available from: <http://www.nature.com/articles/s41591-021-01318-5>
28. Wang P, Wang M, Yu J, et al. Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization [Internet]. *Microbiology*; 2021 [cited 2021 Mar 30]. Available from: <http://biorxiv.org/lookup/doi/10.1101/2021.03.01.433466>
29. Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell* [Internet] 2021 [cited 2021 Mar 30];S0092867421002269. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0092867421002269>
30. Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications. *N Engl J Med* [Internet] 2021 [cited 2021 Mar 26];NEJMc2100362. Available from: <http://www.nejm.org/doi/10.1056/NEJMc2100362>
31. World Health Organization. Diagnostic testing for SARS-CoV-2. Available from: <https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2>
32. World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for COVID-19. Available from: <https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19>
33. Krammer F. Correlates of protection from SARS-CoV-2 infection. *The Lancet* [Internet] 2021 [cited 2021 Apr 22];397(10283):1421–3. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0140673621007820>

© World Health Organization 2021. Some rights reserved. This work is available under the [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/) licence.

WHO reference number: [WHO/2019-nCoV/Sci\\_Brief/Natural\\_immunity/2021.1](https://www.who.int/publications/i/item/WHO/2019-nCoV/Sci_Brief/Natural_immunity/2021.1)